Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
This page provides a historical news archive for Cerevel Therapeutics Holdings, Inc. (formerly Nasdaq: CERE), a neuroscience-focused biopharmaceutical company that became part of AbbVie following the completion of an acquisition announced by AbbVie on August 1, 2024. Before the transaction, Cerevel regularly issued updates on its clinical pipeline, corporate strategy and capital raising activities.
News items for Cerevel include detailed announcements on its key investigational therapies such as emraclidine, tavapadon, darigabat, CVL-871 and CVL-354. These releases cover topics like Phase 2 and Phase 3 trial designs, topline clinical results, regulatory designations and development plans in schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, Parkinson’s disease, mood disorders and related neuroscience indications. For example, Cerevel announced positive topline results from the pivotal Phase 3 TEMPO-3 adjunctive trial of tavapadon in people living with Parkinson’s disease.
Investors and researchers can also review historical corporate and financial communications, including quarterly financial results, business updates, investor webcasts, and the October 2023 public offering of common stock that Cerevel stated would support operations and planned data readouts. In addition, the archive reflects transaction-related news, such as the December 6, 2023 joint announcement by AbbVie and Cerevel of a definitive acquisition agreement, and subsequent commentary from law firms examining the terms of the merger.
Although CERE shares are no longer expected to trade following the closing of the AbbVie acquisition, this news history remains useful for understanding how Cerevel’s neuroscience programs evolved, how management communicated clinical milestones, and how the acquisition rationale was framed by AbbVie. Users interested in ongoing development of these assets should consult AbbVie’s current disclosures, while using this page as a record of Cerevel’s standalone public-company era.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO, Tony Coles, M.D., will present at the 43rd Annual Cowen Health Care Conference. The presentation is scheduled for March 6, 2023, at 9:10 a.m. EST, and can be accessed via a live webcast on Cerevel's investor relations website. Cerevel is focused on neuroscience diseases, offering a diversified pipeline that includes five clinical-stage therapies targeting conditions like schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson's disease. A replay of the presentation will also be available on their website.
Cerevel Therapeutics (CERE) announced significant developments in its clinical pipeline and financial results for 2022. The company is currently enrolling participants in a Phase 1 trial for emraclidine targeted at Alzheimer’s disease psychosis, while its Phase 2 trials for schizophrenia are on track for data release in 1H 2024. As of December 31, 2022, Cerevel reported cash and equivalents of $950 million, projected to fund operations through 2025. Research and development expenses rose to $280.3 million, driven by ongoing clinical programs. Additionally, President Abraham Ceesay will depart on March 9, 2023.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter and full year 2022 financial results on February 22, 2023, prior to U.S. market open. A conference call will follow at 8:00 a.m. ET that same day. Investors can register for the call to receive dial-in details and access a live webcast on the company's website. Cerevel focuses on treating neuroscience diseases with a diversified pipeline of five clinical-stage therapies addressing conditions like Parkinson’s and epilepsy. The company emphasizes a targeted neurocircuitry approach and is engaged in ongoing R&D and potential collaborations.
Cerevel Therapeutics (Nasdaq: CERE) has announced the initiation of a Phase 1 trial for emraclidine, aimed at treating Alzheimer’s disease psychosis. Additionally, a Phase 2 trial for darigabat, targeting panic disorder, is set to begin in Q2 2023. The company is focused on expanding its neuroscience drug pipeline, addressing conditions like schizophrenia, epilepsy, and Parkinson's disease. Upcoming data readouts and a cash runway extending into 2025 position Cerevel to advance its novel therapies. A presentation at the J.P. Morgan Healthcare Conference is scheduled for January 10, 2023.
Cerevel Therapeutics (Nasdaq: CERE) has announced that CEO Tony Coles, M.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The presentation is scheduled for 8:15 a.m. PST/11:15 a.m. EST, followed by a Q&A session with the executive team. Investors can access the live webcast on the company’s investor relations page, with a replay available later. Cerevel focuses on neuroscience diseases, with a diverse pipeline of investigational therapies targeting conditions like Parkinson’s, epilepsy, schizophrenia, and dementia-related apathy.
Cerevel Therapeutics announced positive results from a Phase 1 trial of emraclidine, a treatment for schizophrenia, indicating no significant increase in blood pressure. At week eight, the mean change in 24-hour ambulatory systolic blood pressure was -2.7 mmHg for the 10 mg dose and -0.4 mmHg for the 30 mg dose. The study confirmed that emraclidine does not cause a blood pressure increase exceeding 3 mmHg, aligning with FDA guidelines. The drug was well-tolerated, with a side effect profile consistent with earlier trials. A comprehensive Phase 2 program is set to read out in early 2024.
Cerevel Therapeutics announced promising results from its Phase 1b clinical trial of emraclidine, a selective muscarinic M4 receptor positive allosteric modulator aimed at treating schizophrenia. Findings showed statistically significant improvements in symptom severity after six weeks compared to placebo, with no major gastrointestinal side effects. The company is moving forward with its Phase 2 development program involving additional clinical trials expected to report in the first half of 2024, highlighting a potential breakthrough in schizophrenia treatment.
Cerevel Therapeutics (Nasdaq: CERE) announced participation in three key investor conferences focused on neuroscience. The events include the Guggenheim Healthcare Talks on November 15, Stifel 2022 Healthcare Conference on November 16, and the Evercore ISI HealthCONx Conference on November 29. Key executives, including Chief Medical Officer Raymond Sanchez and CEO Tony Coles, will lead engaging discussions. Live webcasts will be accessible via their investor relations webpage, with replays available post-event. Cerevel aims to advance treatments for neuroscience diseases.
Cerevel Therapeutics (CERE) has successfully completed a $599 million dual convertible debt and equity financing to enhance its neuroscience therapeutics pipeline. The company initiated the EMPOWER-3 trial for emraclidine in schizophrenia and received FDA Fast Track designation for the same drug in Alzheimer’s disease psychosis, with a Phase 1 trial expected by year-end 2022. As of September 30, 2022, Cerevel holds $1,030 million in cash and equivalents, expected to support operations into 2025.
Cerevel Therapeutics (Nasdaq: CERE) will announce its third quarter 2022 financial results on November 8, 2022, prior to the market opening. Management will host a conference call on the same day at 8:00 a.m. ET to discuss these results and recent business developments. Investors can register for the call through a provided link for dial-in information. Cerevel is focused on neuroscience diseases, boasting a pipeline with five clinical-stage therapies aimed at conditions such as Parkinson’s and schizophrenia.